타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd) Daiichi Sankyo / AstraZeneca·TROP2 50 trials | ||||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Opdivo (nivolumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) | Datroway (datopotamab deruxtecan-dlnk) |
Overview Company | Merck | Bristol Myers Squibb | AstraZeneca | Roche / Genentech | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | PD-1 | PD-1 | PD-L1 | PD-L1 | TROP2 |
Overview Indication | Multiple solid tumors | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior therapies; first-line TNBC unsuitable for PD-1/PD-L1 therapy. Consult current US label. |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | escape detection by the immune system | resistance to existing therapies | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. |
Positioning Development positioning | — | — | — | — | Indication-specific; includes 1L TNBC unsuitable for PD-1/PD-L1 therapy |
Technology Payload | — | — | — | — | DXd (exatecan derivative, topoisomerase I inhibitor) |
Technology Linker | — | — | — | — | Tetrapeptide-based cleavable maleimide linker, DAR ~4 |
Technology DAR | — | — | — | — | DAR 4 |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse | Rat, Hamster |
Toxicology Animal (cat.) | — | NHP | — | — | — |
Toxicology Major finding | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Toxicology CRS | N/A | N/A (checkpoint inhibitor) | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Clinical Selected reported efficacy | — | — | — | — | ORR 64% |
Clinical Reported ORR | — | — | — | — | 64% vs 30% (chemotherapy) |
Clinical Reported PFS | — | — | — | — | 10.8 months vs 5.6 months (chemotherapy) |
Clinical Reported OS | — | — | — | — | 23.7 months vs 18.7 months (chemotherapy) |
Clinical Result source | — | — | — | — | FDA approval report 2026-05-22 — TROPION-Breast02 (NCT05374512) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | — | — | — | NCT05374512 |
Preclinical Animal (cat.) | — | — | — | — | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd) Daiichi Sankyo / AstraZeneca·TROP2 50 trials | ||||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Opdivo (nivolumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) | Datroway (datopotamab deruxtecan-dlnk) |
Overview Company | Merck | Bristol Myers Squibb | AstraZeneca | Roche / Genentech | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | PD-1 | PD-1 | PD-L1 | PD-L1 | TROP2 |
Overview Indication | Multiple solid tumors | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior therapies; first-line TNBC unsuitable for PD-1/PD-L1 therapy. Consult current US label. |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | escape detection by the immune system | resistance to existing therapies | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. |
Positioning Development positioning | — | — | — | — | Indication-specific; includes 1L TNBC unsuitable for PD-1/PD-L1 therapy |
Technology Payload | — | — | — | — | DXd (exatecan derivative, topoisomerase I inhibitor) |
Technology Linker | — | — | — | — | Tetrapeptide-based cleavable maleimide linker, DAR ~4 |
Technology DAR | — | — | — | — | DAR 4 |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse | Rat, Hamster |
Toxicology Animal (cat.) | — | NHP | — | — | — |
Toxicology Major finding | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Toxicology CRS | N/A | N/A (checkpoint inhibitor) | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Clinical Selected reported efficacy | — | — | — | — | ORR 64% |
Clinical Reported ORR | — | — | — | — | 64% vs 30% (chemotherapy) |
Clinical Reported PFS | — | — | — | — | 10.8 months vs 5.6 months (chemotherapy) |
Clinical Reported OS | — | — | — | — | 23.7 months vs 18.7 months (chemotherapy) |
Clinical Result source | — | — | — | — | FDA approval report 2026-05-22 — TROPION-Breast02 (NCT05374512) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | — | — | — | NCT05374512 |
Preclinical Animal (cat.) | — | — | — | — | Mouse, In vitro |
추천 비교
추천 비교